Article Details

Coherus Agrees to Acquire a Biosimilar EYLEA Candidate from Klinge Biopharma

Retrieved on: 2023-01-13 17:41:27

Tags for this article:

Click the tags to see associated articles and topics

Coherus Agrees to Acquire a Biosimilar EYLEA Candidate from Klinge Biopharma. View article details on hiswai:

Excerpt

... commercialization rights to FYB203, a biosimilar referencing EYLEA (aflibercept) from Klinge Biopharma GmbH (“Klinge Biopharma”) in the US.

Article found on: www.jdsupra.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up